Ramak Ajideh - Biotechnology Research Centre, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
Elnaz Faghfuri - Digestive Disease Research Center, Ardabil University of Medical Sciences, Ardabil, Iran
Mina Hosseini - Biotechnology Research Centre, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
Mohammad Hossein Yazdi - Recombinant Vaccine Research Centre, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
Rouhollah Mirjani - Department of Genetics and Advanced Medical Technology, Faculty of Medicine, AJA University of Medical Sciences, Tehran, Iran
Zargham Sepehrizadeh - Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
Ahmad Reza Shahverdi - Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

Background: Tellurium- containing compounds are suggested as the treatment agents for different diseases. This study aimed to synthesize tellurium nanoparticles (TeNPs) and study their in vitro and in vivo effects on tumour cells.Method: In this experimental study, the synthesis of TeNPs in an aqueous solution was achieved with lactose as a reducing agent. The cells (۲×۱۰۴) were seeded, in triplicate, in ۹۶-well plates and exposed to different concentrations of TeNPs for ۴۸ hours. The determination of cell viability was done by MTT assay. In vivo studies were performed using breast cancer-bearing mice treated with TeNPs at different doses via intraperitoneal (IP) and intravenous (IV) injections.Results: After ۴۸ hours of treatment with TeNPs at different concentrations, cancer cell line viability was significantly decreased compared with control at almost all concentrations. Moreover, the IC۵۰ of TeNPs in the non-cancerous cell line CHO (۵۰.۵۳ μg/mL) was far above that of EJ۱۳۸ (۲۹.۶۰ μg/mL) and ۴T۱ (۷.۴۱ μg/mL) cell lines, revealing their lower toxicity in normal cells in comparison with cancer cells. The in vivo study's findings also showed that both delivery methods significantly inhibited tumor development, and that breast cancer-bearing mice lived longer than control mice, particularly when the largest dosage (۴۰۰ μg, injected three times a week) was used.Conclusion: These results demonstrate TeNPs as promising therapeutic agents for cancer treatment. However, further investigation is still needed to determine the in vitro and in vivo anticancer mechanisms of TeNPs.

Anticancer, Cytotoxicity, Cell Line, Experimental mammary Neoplasm, Metal Nanoparticles